Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11541937 | 0.89 | CYP2D6 (0.60) | CYP2D6CYP19A1CYP2C9CYP2C19MET | |
| SCHEMBL29683245 | 0.79 | CYP19A1 (0.52) | CYP2D6CYP19A1CYP2C9CYP2C19RAB9A | |
| SCHEMBL17246864 | 0.79 | CYP19A1 (0.52) | CYP2D6CYP19A1CYP2C9CYP2C19RAB9A | |
| SCHEMBL3977992 | 0.79 | BCHE (0.57) | RPS6KA3KMT2ARAB9AMAPTALDH1A1 | |
| SCHEMBL999538 | 0.78 | CYP19A1 (0.51) | CYP2D6CYP19A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL5992577 | 0.78 | CYP2D6 (0.51) | CYP2D6CYP19A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL31140236 | 0.78 | CYP2D6 (0.56) | CYP2D6CYP19A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL8467929 | 0.78 | CYP2D6 (0.51) | CYP2D6CYP19A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL1109087 | 0.78 | CYP2D6 (0.56) | CYP2D6CYP19A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL13457927 | 0.78 | CYP19A1 (0.51) | CYP2D6CYP19A1CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1720238-A | Neurologically-active compounds | PRANA BIOTECHNOLOGY LTD (AU) | 2006-01-11 | — | — | CN | claimed |
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| CN-109661387-B | Composition for treating pulmonary fibrosis | 维克图斯生物系统有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11401245-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2022-08-02 | — | — | US | disclosed |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-05-06 | — | — | US | disclosed |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-05-06 | — | — | US | disclosed |
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-02-16 | — | — | US | disclosed |
| US-20200093135-A1 | SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL | EMEKATECH LLC (US) | 2020-03-26 | — | — | US | disclosed |
| US-20190270712-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2019-09-05 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| CN-1720238-A | Neurologically-active compounds | PRANA BIOTECHNOLOGY LTD (AU) | 2006-01-11 | — | — | CN | disclosed |
| CN-1207322-C | Method for producing polycarbonate resin raw material and polycarbonate resin | IDEMITSU PETROCHEMICAL CO (JP) | 2005-06-22 | — | — | CN | disclosed |
| CN-1622965-A | Aromatic polycarbonate resin, process for producing the same, molding material for optical parts, and optical parts | IDEMITSU KOSAN CO (JP) | 2005-06-01 | — | — | CN | disclosed |
| CN-1364176-A | Processes for producing raw polycarbonate resin material and producing polycarbonate resin | IDEMITSU PETROCHEMICAL CO (JP) | 2002-08-14 | — | — | CN | disclosed |
| WO-1997019374-A1 | POLARIZER FILMS COMPRISING AROMATIC LIQUID CRYSTALLINE POLYMERS COMPRISING DICHROIC DYES IN THEIR MAIN CHAINS | HOECHST CELANESE CORPORATION (US) | 1997-05-29 | — | — | WO | disclosed |
| US-5393860-A | Functional monomers for high performance polymers | HOECHST CELANESE CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0204172-B1 | PHENYLPYRAZINE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION AND USE | SUNTORY LIMITED (JP) | 1990-09-19 | — | — | EP | disclosed |
| US-4755514-A | Phenylpyrazine derivatives and thrombolytic agent | SUNTORY LIMITED (JP) | 1988-07-05 | — | — | US | disclosed |
| EP-0204172-A2 | Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use | SUNTORY LIMITED (JP) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | CYP2D6 4733/4885CYP19A1 4771/4885CYP2C9 4817/4885 |
| US-11401245-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | CYP2D6 4733/4885CYP19A1 4771/4885CYP2C9 4817/4885 |
| US-20190270712-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | ELANE, MMP1, CCL11 | CYP2D6 4733/4885CYP19A1 4771/4885CYP2C9 4817/4885 |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | ELANE, MMP1, CCL11 | CYP2D6 4733/4885CYP19A1 4771/4885CYP2C9 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.